Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 2/20 | 0.45 |
| ▸ | Q9HBH1 | 1/20 | 0.43 | |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.41 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | CHRND | Q07001 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25100592 | 0.86 | SIRT2 (0.42) | KLKB1PDFSSTR3SIRT2SIRT1 | |
| SCHEMBL17090699 | 0.83 | KLKB1 (0.46) | KLKB1PDFPLGSSTR3CALCRL | |
| SCHEMBL16984908 | 0.82 | CALCRL (0.51) | PLGSSTR3CALCRLSIRT2SIRT1 | |
| SCHEMBL16854865 | 0.81 | CALCRL (0.54) | PLGSSTR3CALCRLLTA4HHDAC4 | |
| SCHEMBL17067271 | 0.81 | KLKB1 (0.47) | KLKB1PDFPLGSSTR3CALCRL | |
| SCHEMBL25052999 | 0.80 | SIRT2 (0.51) | SIRT2SIRT1TLR2 | |
| SCHEMBL26283842 | 0.78 | CPB1 (0.49) | KLKB1SIRT2SIRT1ROCK2 | |
| SCHEMBL18738463 | 0.77 | SMN1; SMN2 (0.45) | KLKB1PDFPLGCALCRLSPHK1 | |
| SCHEMBL24864663 | 0.77 | KLKB1 (0.48) | KLKB1PDFPLGSSTR3CALCRL | |
| SCHEMBL27410343 | 0.77 | CA1 (0.53) | CA1CA2SIRT2SIRT1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020489-B2 | Immunoconjugates with an intracellularly-cleavable linkage | IMMUNOMEDICS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020489-B2 | Immunoconjugates with an intracellularly-cleavable linkage | CD47, CD44, DNPEP | KLKB1 314/4885PDF 600/4885PLG 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.